Nakajo–Nishimura syndrome and related proteasome-associated autoinflammatory syndromes

References

• Arima K, Kinoshita A, Mishima H, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A. 2011;108:14914–14919. doi:10.1073/pnas.110601510821852578
   PubMed Web of Science ®Google Scholar
• Kitamura A, Maekawa Y, Uehara H, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest. 2011;121:4150–4160. doi:10.1172/JCI5841421881205
   PubMed Web of Science ®Google Scholar
• Liu Y, Ramot Y, Torrelo A, et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012;64:895–907. doi:10.1002/art.3336821953331
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Xing C, DeMartino GN, et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet. 2010;87:866–872. doi:10.1016/j.ajhg.2010.10.03121129723
   PubMed Web of Science ®Google Scholar
• Nakajo A. Secondary hypertrophic osteoperiostosis with pernio. J Dermatol Urol. 1939;45:77–86.
   Google Scholar
• Nishimura N, Deki T, Kato S. Hypertrophic pulmonary osteo-arthropathy with pernio-like eruption in the two families. J Dermatol Venereol. 1950;60:136–141.
   Google Scholar
• Kitano Y, Matsunaga E, Morimoto T, Okada N, Sano S. A syndrome with nodular erythema, elongated and thickened fingers, and emaciation. Arch Dermatol. 1985;121:1053–1056.4026345
   PubMedGoogle Scholar
• Kanazawa N, Arima K, Ida H, Yoshiura K, Furukawa F. [Nakajo-Nishimura syndrome]. Jpn J Clin Immunol. 2011;34:388–400.
   PubMedGoogle Scholar
• Murata S, Yashiroda H, Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol. 2009;10:104–115. doi:10.1038/nrm263019165213
   PubMed Web of Science ®Google Scholar
• Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med. 2009;30:191–296. doi:10.1016/j.mam.2009.04.00119371762
   PubMed Web of Science ®Google Scholar
• Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. 2011;7:137–150. doi:10.1038/nrendo.2010.19921079616
   PubMed Web of Science ®Google Scholar
• Crow YJ, Rehwinkel J. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet. 2009;18:R130–R136. doi:10.1093/hmg/ddp29319808788
   PubMed Web of Science ®Google Scholar
• Oyanagi K, Sasaki K, Ohama E, et al. An autopsy case of a syndrome with muscular atrophy, decreased subcutaneous fat, skin eruption and hyper gamma-globulinemia: peculiar vascular changes and muscle fiber degeneration. Acta Neuropathol. 1987;73:313–319.3618123
   PubMed Web of Science ®Google Scholar
• Lamprecht P, Moosig F, Adam-Klages S, et al. Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS. Ann Rheum Dis. 2004;63:1518–1520. doi:10.1136/ard.2003.01673315479908
   PubMed Web of Science ®Google Scholar
• Torrelo A, Patel S, Colmenero I, et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J Am Acad Dermatol. 2010;62:489–495. doi:10.1016/j.jaad.2009.04.04620159315
   PubMed Web of Science ®Google Scholar
• Garg A, Hernandez MD, Sousa AB, et al. An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy. J Clin Endocrinol Metab. 2010;95:E58–E63. doi:10.1210/jc.2010-048820534754
   PubMed Web of Science ®Google Scholar
• Ramot Y, Czarnowicki T, Maly A, Navon-Elkan P, Zlotogorski A. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a case report. Pediatr Dermatol. 2011;28:538–541. doi:10.1111/j.1525-1470.2010.01163.x20553399
   PubMed Web of Science ®Google Scholar
• Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest. 2015;125:4196–4211. doi:10.1172/JCI8126026524591
   PubMed Web of Science ®Google Scholar
• de Jesus AA, Brehm A, VanTries R, et al. Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4. J Allergy Clin Immunol. 2019;143:1939–1943.e1938. doi:10.1016/j.jaci.2018.12.101230664889
   PubMed Web of Science ®Google Scholar
• Poli MC, Ebstein F, Nicholas SK, et al. Heterozygous truncating variants in POMP escape nonsense-mediated decay and cause a unique immune dysregulatory syndrome. Am J Hum Genet. 2018;102:1126–1142. doi:10.1016/j.ajhg.2018.04.01029805043
   PubMed Web of Science ®Google Scholar
• Kury S, Besnard T, Ebstein F, et al. De novo disruption of the proteasome regulatory subunit PSMD12 causes a syndromic neurodevelopmental disorder. Am J Hum Genet. 2017;100:352–363. doi:10.1016/j.ajhg.2017.01.00328132691
   PubMed Web of Science ®Google Scholar
• Picard C, Bobby Gaspar H, Al-Herz W, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38:96–128. doi:10.1007/s10875-017-0464-929226302
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15:87–103. doi:10.1038/nri378725614319
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev. 2009;227:54–65. doi:10.1111/j.1600-065X.2008.00727.x19120475
   PubMed Web of Science ®Google Scholar
• Kunimoto K, Honda-Ozaki F, Saito MK, Furukawa F, Kanazawa N. Beneficial effect of methotrexate on a child case of Nakajo-Nishimura syndrome. J Dermatol. 2019. doi:10.1111/1346-8138.14907
   Web of Science ®Google Scholar
• Cavalcante MP, Brunelli JB, Miranda CC, et al. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature-a rare case with a novel mutation. Eur J Pediatr. 2016;175:735–740. doi:10.1007/s00431-015-2668-426567544
   PubMed Web of Science ®Google Scholar
• Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128:3041–3052. doi:10.1172/JCI9881429649002
   PubMed Web of Science ®Google Scholar
• Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104:364–373. doi:10.1002/cpt.93629134648
   PubMed Web of Science ®Google Scholar
• Boyadzhiev M, Marinov L, Boyadzhiev V, Iotova V, Aksentijevich I, Hambleton S. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome. Pediatr Rheumatol Online J. 2019;17:19. doi:10.1186/s12969-019-0322-931046790
   PubMed Web of Science ®Google Scholar